CO6940411A2 - 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk - Google Patents

4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk

Info

Publication number
CO6940411A2
CO6940411A2 CO14008868A CO14008868A CO6940411A2 CO 6940411 A2 CO6940411 A2 CO 6940411A2 CO 14008868 A CO14008868 A CO 14008868A CO 14008868 A CO14008868 A CO 14008868A CO 6940411 A2 CO6940411 A2 CO 6940411A2
Authority
CO
Colombia
Prior art keywords
benzamides
imidazotriazin
imidazopyridazin
btk inhibitors
btk
Prior art date
Application number
CO14008868A
Other languages
English (en)
Spanish (es)
Inventor
Tjeerd A Barf
Christian Gerardus Johannes Maria Jans
De Adrianus Petrus Antonius Man
Oubrie Arthur A
A Raaijmakers Hans C
Johannes Bernardus Rewinkel
Jan-Gerard Sterrenburg
H M Wijkmans Jacobus C
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47557677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6940411(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CO6940411A2 publication Critical patent/CO6940411A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO14008868A 2011-07-19 2014-01-17 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk CO6940411A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509397P 2011-07-19 2011-07-19
EP11174578 2011-07-19

Publications (1)

Publication Number Publication Date
CO6940411A2 true CO6940411A2 (es) 2014-05-09

Family

ID=47557677

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14008868A CO6940411A2 (es) 2011-07-19 2014-01-17 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk

Country Status (38)

Country Link
US (7) US9290504B2 (h)
EP (4) EP3689878B1 (h)
JP (6) JP5826931B2 (h)
KR (2) KR101802689B1 (h)
CN (2) CN103889987B (h)
AU (4) AU2012285987C1 (h)
BR (1) BR112014001255B1 (h)
CA (1) CA2841886C (h)
CL (1) CL2014000130A1 (h)
CO (1) CO6940411A2 (h)
CR (1) CR20140030A (h)
CY (2) CY2021010I2 (h)
DK (2) DK2734522T3 (h)
DO (1) DOP2014000008A (h)
EA (2) EA034558B1 (h)
EC (1) ECSP14013217A (h)
ES (3) ES2904707T3 (h)
GT (1) GT201400009A (h)
HR (2) HRP20212021T1 (h)
HU (3) HUE041987T2 (h)
IL (3) IL230511B (h)
IN (1) IN2014CN00408A (h)
LT (1) LT2734522T (h)
MA (1) MA35348B1 (h)
MX (1) MX342983B (h)
MY (1) MY192354A (h)
PE (1) PE20141681A1 (h)
PH (2) PH12014500148A1 (h)
PL (2) PL2734522T3 (h)
PT (1) PT3689878T (h)
RS (2) RS58177B1 (h)
SG (1) SG10201605913VA (h)
SI (2) SI2734522T1 (h)
SM (2) SMT201900029T1 (h)
TN (1) TN2014000027A1 (h)
UA (1) UA115312C2 (h)
WO (1) WO2013010868A1 (h)
ZA (1) ZA202109164B (h)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101113A1 (en) * 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
ES2604191T3 (es) 2011-05-17 2017-03-03 Principia Biopharma Inc. Inhibidores de tirosina quinasas
CA2841080A1 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
DK2734522T3 (en) * 2011-07-19 2019-02-18 Merck Sharp & Dohme 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
EP3181567B9 (en) 2012-09-10 2025-09-24 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
EP2900673A4 (en) * 2012-09-26 2016-10-19 Univ California IRE1 MODULATION
CN104822663B (zh) * 2012-10-04 2017-03-08 犹他大学研究基金会 作为酪氨酸受体激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物
MX375194B (es) 2012-11-01 2025-03-06 Infinity Pharmaceuticals Inc Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
EP2948458B1 (en) 2013-01-23 2019-05-01 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
ES2706150T3 (es) 2013-07-31 2019-03-27 Merck Patent Gmbh Piridinas, pirimidinas y pirazinas, como inhibidores de BTK y sus usos
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
KR20160093062A (ko) 2013-12-05 2016-08-05 아세르타 파마. 비.브이. Pi3k 억제제 및 btk 억제제의 치료적 조합
WO2015095102A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Btk inhibitors
EP3082809B1 (en) 2013-12-20 2021-01-20 Merck Sharp & Dohme Corp. Btk inhibitors
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
MX372673B (es) 2014-02-21 2020-03-25 Principia Biopharma Inc Un inhibidor de btk para usarse en el tratamiento de penfigo y sales y formas sólidas del mismo.
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
WO2015193740A2 (en) * 2014-06-17 2015-12-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
WO2016019233A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
TW201618774A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
DK3179991T3 (da) 2014-08-11 2021-12-06 Acerta Pharma Bv Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor
TW201618773A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
TW201609099A (zh) 2014-08-11 2016-03-16 艾森塔製藥公司 使用布魯頓（Ｂｒｕｔｏｎ）氏酪胺酸激酶（ＢＴＫ）抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
US9951047B2 (en) 2014-08-18 2018-04-24 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
EP3191098A4 (en) * 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016055982A1 (en) * 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
WO2016100914A1 (en) * 2014-12-18 2016-06-23 Gourlay Steven Treatment of pemphigus
WO2016106629A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106625A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106627A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106626A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106623A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016128912A1 (en) * 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
WO2016152907A1 (ja) 2015-03-25 2016-09-29 国立研究開発法人国立がん研究センター 胆管癌治療剤
WO2016161571A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. Indazole and azaindazole btk inhibitors
WO2016192074A1 (en) * 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016210165A1 (en) 2015-06-24 2016-12-29 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP3317281B1 (en) 2015-07-02 2020-04-22 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
WO2017033113A1 (en) * 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
MA44909A (fr) * 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
JP6890602B2 (ja) 2015-11-06 2021-06-18 アセルタ ファーマ ビー．ブイ． ブルトン型チロシンキナーゼのイミダゾピラジン阻害剤
WO2017104739A1 (ja) 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
ES2839408T3 (es) 2016-01-13 2021-07-05 Acerta Pharma Bv Combinaciones terapéuticas de un antifolato y un inhibidor de BTK
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(oxane-3-yl)piperazine-1-yl)penta-2-ananitrile
AU2017287553B2 (en) * 2016-06-30 2020-02-06 Hangzhou BANGSHUN Pharmaceutical Co., Ltd Imidazopyrazinamine phenyl derivative and use thereof
WO2018002958A1 (en) * 2016-06-30 2018-01-04 Sun Pharma Advanced Research Company Limited Novel hydrazide containing compounds as btk inhibitors
CN109851620B (zh) * 2016-08-17 2020-08-07 深圳市塔吉瑞生物医药有限公司 用于抑制酪氨酸激酶活性的稠合双环类化合物
CN113416194A (zh) 2016-10-05 2021-09-21 杭州领业医药科技有限公司 Acp-196的晶型及其制备方法和药物组合物
CN107056786B (zh) * 2016-10-14 2019-05-07 苏州明锐医药科技有限公司 阿卡替尼的制备方法
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
MX388457B (es) * 2016-12-21 2025-03-20 Acerta Pharma Bv Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
WO2018115965A1 (en) 2016-12-23 2018-06-28 Acerta Pharma Bv Solid forms of imidazopyrazine compounds
CN106588937B (zh) 2017-01-16 2018-09-21 东莞市真兴贝特医药技术有限公司 咪唑并吡嗪类化合物及其制备方法和应用
WO2018134786A1 (en) 2017-01-19 2018-07-26 Acerta Pharma B.V. Compositions and methods for the assessment of drug target occupancy for bruton's tyrosine kinase
CN106831787B (zh) 2017-01-20 2018-10-23 成都倍特药业有限公司 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用
CN110312723B (zh) * 2017-02-20 2022-02-11 杭州领业医药科技有限公司 Acp-196盐的晶型、其制备方法、药物组合物和用途
US10314844B2 (en) 2017-02-24 2019-06-11 Gilead Sciences, Inc. Inhibitors of Bruton's tyrosine kinase
WO2018156895A1 (en) 2017-02-24 2018-08-30 Gilead Sciences, Inc. Inhibitors of bruton's tyrosine kinase
MX2019011116A (es) 2017-03-22 2020-02-05 Liao Xibin Inhibidores de la tirosina quinasa de bruton.
JOP20190233A1 (ar) 2017-04-14 2019-10-02 Biogen Ma Inc نظائر بنزوازيبين بوصفها عوامل مثبطة لتيروزين كيناز بروتون
CA3058682A1 (en) * 2017-04-20 2018-10-25 Apotex Inc. Processes for the preparation of acalabrutinib and intermediates thereof
WO2018229613A1 (en) * 2017-06-13 2018-12-20 Dr. Reddy's Laboratories Limited Solid forms of acalabrutinib and process for preparation thereof
CN107522701B (zh) * 2017-09-01 2019-11-08 苏州富士莱医药股份有限公司 一种治疗慢性淋巴细胞白血病的BTK抑制剂Acalabrutinib的合成方法
CN107602564B (zh) * 2017-09-20 2019-08-30 南京亘泰医药技术有限公司 布鲁顿酪氨酸激酶抑制剂
WO2019058348A1 (en) 2017-09-25 2019-03-28 Astrazeneca Ab COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER
CN109836416B (zh) * 2017-11-27 2023-02-03 苏州鹏旭医药科技有限公司 一种化合物的制备方法
US11161851B2 (en) 2017-11-06 2021-11-02 Suzhou Pengxu Pharmatech Co. Ltd. Processes to produce acalabrutinib
EP3736273A4 (en) * 2018-01-05 2021-02-24 Crystal Pharmaceutical (Suzhou) Co., Ltd. NEW ACALABRUTINIB CRYSTAL FORM AND THE MANUFACTURING METHOD AND USE OF IT
CN108250186B (zh) * 2018-02-07 2020-01-14 杭州科巢生物科技有限公司 Acalabrutinib及其中间体的合成方法
CN110256438B (zh) * 2018-03-12 2020-07-17 新发药业有限公司 一种阿可替尼的制备方法
MX2020008610A (es) 2018-03-28 2020-09-21 Eisai R&D Man Co Ltd Agente terapeutico para carcinoma hepatocelular.
US20210113568A1 (en) 2018-04-27 2021-04-22 Ono Pharmaceutical Co., Ltd. PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT
TW202014184A (zh) 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
WO2019239374A1 (en) 2018-06-13 2019-12-19 Acerta Pharma B.V. Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
MA52966A (fr) 2018-06-19 2021-04-28 Regeneron Pharma Anticorps anti-facteur xii/xiia et leurs utilisations
EP3587421A1 (en) 2018-06-29 2020-01-01 Sandoz AG Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
US12024520B2 (en) * 2018-08-29 2024-07-02 Acerta Pharma B.V. Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide
WO2020053795A2 (en) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Process for the preparation of acalabrutinib and its intermediates
WO2020065667A1 (en) 2018-09-25 2020-04-02 Cipla Limited Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
CN109020977B (zh) * 2018-10-26 2020-11-13 安庆奇创药业有限公司 一种Acalabrutinib的制备方法
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
CN111377928A (zh) * 2018-12-28 2020-07-07 南京艾德凯腾生物医药有限责任公司 一种制备Acalabrutinib的方法
CN111377929A (zh) * 2018-12-28 2020-07-07 南京艾德凯腾生物医药有限责任公司 一种可用于治疗白血病阿卡替尼(Acalabrutinib)制备的方法
CN118955505A (zh) 2019-01-18 2024-11-15 杭州邦顺制药有限公司 布鲁顿酪氨酸激酶抑制剂
US20220194945A1 (en) * 2019-02-27 2022-06-23 Optikira, LLC Imidazolopyridine Compounds For IRE1 Inhibition
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020198429A1 (en) 2019-03-27 2020-10-01 Assia Chemical Industries Ltd Solid state forms of acalabrutinib
WO2020225831A1 (en) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021038540A1 (en) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Cycloalkylidene carboxylic acids and derivatives as btk inhibitors
CN110563733A (zh) * 2019-09-12 2019-12-13 安帝康（无锡）生物科技有限公司 作为选择性btk抑制剂的咪唑并吡嗪类化合物
AU2020365951A1 (en) 2019-10-14 2022-06-02 Principia Biopharma Inc. Methods for treating immune thrombocytopenia by administering (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
JP7575454B2 (ja) 2019-11-04 2024-10-29 アストラゼネカ・アクチエボラーグ Ｂ細胞悪性腫瘍を処置するためのアカラブルチニブとカピバセルチブとの治療的組み合わせ
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
IL294785A (en) 2020-01-22 2022-09-01 Principia Biopharma Inc Crystalline forms of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
IL298872A (en) 2020-06-19 2023-02-01 Acerta Pharma Bv Acalabrutinib maleate dosage forms
CN112386597B (zh) * 2020-10-15 2022-03-15 天津济坤医药科技有限公司 泽布替尼在制备治疗肺纤维化疾病药物中的应用
CN113264938B (zh) * 2021-07-21 2021-11-02 北京鑫开元医药科技有限公司 一种咪唑并[1,5-a]吡嗪-8-胺类化合物、制备方法、药物组合物和应用
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
WO2025125383A1 (en) 2023-12-11 2025-06-19 Synthon B.V. Crystalline forms of acalabrutinib hydrogen maleate
US12414950B1 (en) 2024-05-21 2025-09-16 Telios Pharma Inc. Methods of treating indolent systemic mastocytosis

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753555C (en) 1998-09-18 2003-07-03 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as protein kinase inhibitors
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
PT1268481E (pt) 1999-09-17 2008-03-19 Abbott Gmbh & Co Kg Inibidores de quinases como agentes terapêuticos
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
TW200530238A (en) 2003-10-15 2005-09-16 Osi Pharm Inc Imidazopyrazine tyrosine kinase inhibitors
PL1740591T3 (pl) * 2004-04-02 2009-11-30 Osi Pharm Inc Heterobicykliczne inhibitory kinazy białkowej podstawione 6,6-bicyklicznym pierścieniem
JP5335432B2 (ja) 2005-11-17 2013-11-06 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー 縮合２環系ｍＴＯＲ阻害剤
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EP2201840B1 (en) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
EP2560007A1 (en) * 2007-03-28 2013-02-20 Pharmacyclics, Inc. Identification of bruton's tyrosine kinase inhibitors
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CN101896177A (zh) 2007-12-13 2010-11-24 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
CN102046179B (zh) * 2008-04-09 2015-01-14 英菲尼提制药公司 脂肪酸酰胺水解酶抑制剂
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CN102918042B (zh) * 2010-02-08 2016-03-09 默沙东有限责任公司 8-甲基-1-苯基-咪唑[1,5-a]吡嗪化合物
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
WO2011152351A1 (ja) 2010-05-31 2011-12-08 小野薬品工業株式会社 プリノン誘導体
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
BR112013029508B1 (pt) 2011-05-17 2022-05-03 Principia Biopharma, Inc. Composto, composição farmacêutica, e, uso do referido composto
US20130178483A1 (en) 2011-06-28 2013-07-11 Pharmacyclics, Inc. Methods and Compositions for Inhibition of Bone Resorption
CA2841080A1 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CA2841887A1 (en) 2011-07-19 2013-01-24 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors
DK2734522T3 (en) * 2011-07-19 2019-02-18 Merck Sharp & Dohme 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4-IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
IL288009B1 (en) 2011-10-19 2025-01-01 Pharmacyclics Llc Use of Bruton's tyrosine kinase inhibitors
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2948458B1 (en) 2013-01-23 2019-05-01 Merck Sharp & Dohme Corp. Btk inhibitors
MX2015011733A (es) 2013-03-14 2016-04-25 Pharmacyclics Llc Combinaciones de inhibidores de la tirosina quinasa de bruton e inhibidores de cyp3a4.
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
BR112015025711A8 (pt) 2013-04-08 2019-12-17 Janssen Pharmaceutica Nv uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)

Also Published As

Publication number Publication date
SMT202100729T1 (it) 2022-01-10
JP7054721B2 (ja) 2022-04-14
AU2012285987A1 (en) 2014-02-06
CA2841886A1 (en) 2013-01-24
JP6749444B2 (ja) 2020-09-02
CN106243113A (zh) 2016-12-21
PH12017500166A1 (en) 2017-09-04
GT201400009A (es) 2017-09-28
EP3495368A1 (en) 2019-06-12
BR112014001255A2 (pt) 2017-02-21
IL266894A (en) 2019-07-31
ES2950569T3 (es) 2023-10-11
MY192354A (en) 2022-08-17
ECSP14013217A (es) 2015-03-31
JP6617130B2 (ja) 2019-12-11
HRP20212021T1 (hr) 2022-04-01
US20160159810A1 (en) 2016-06-09
IL291489A (en) 2022-05-01
HRP20190135T1 (hr) 2019-03-22
US20160151364A1 (en) 2016-06-02
CN106243113B (zh) 2018-12-18
SG10201605913VA (en) 2016-09-29
JP2016034968A (ja) 2016-03-17
ES2708224T3 (es) 2019-04-09
JP2014520870A (ja) 2014-08-25
NZ620085A (en) 2016-05-27
DOP2014000008A (es) 2014-04-30
US20140155385A1 (en) 2014-06-05
LT2734522T (lt) 2019-02-11
HUS2100012I1 (hu) 2021-05-28
EP3495368B1 (en) 2023-05-31
AU2019275591A1 (en) 2020-01-02
IL230511B (en) 2019-05-30
TN2014000027A1 (en) 2015-07-01
US20230331729A1 (en) 2023-10-19
BR112014001255B1 (pt) 2019-07-02
US10239883B2 (en) 2019-03-26
DK2734522T3 (en) 2019-02-18
PT3689878T (pt) 2022-01-05
CY2021010I1 (el) 2021-06-25
JP2020189865A (ja) 2020-11-26
US20210230166A1 (en) 2021-07-29
PH12014500148A1 (en) 2014-03-31
EA201490300A1 (ru) 2014-05-30
MX342983B (es) 2016-10-19
AU2016203837B2 (en) 2018-01-25
KR101702727B1 (ko) 2017-02-06
RS58177B1 (sr) 2019-03-29
HUE041987T2 (hu) 2019-06-28
US9758524B2 (en) 2017-09-12
PE20141681A1 (es) 2014-11-14
CR20140030A (es) 2014-06-03
EP4249076A2 (en) 2023-09-27
KR101802689B1 (ko) 2017-11-28
EP3689878A1 (en) 2020-08-05
AU2019275591B2 (en) 2020-10-01
JP6251220B2 (ja) 2017-12-20
CA2841886C (en) 2016-08-16
JP2019108395A (ja) 2019-07-04
AU2012285987C1 (en) 2016-09-08
MX2014000746A (es) 2014-05-07
KR20160117642A (ko) 2016-10-10
JP5826931B2 (ja) 2015-12-02
AU2012285987B2 (en) 2016-03-10
HUE056249T2 (hu) 2022-02-28
RS62760B1 (sr) 2022-01-31
ES2904707T3 (es) 2022-04-05
SI3689878T1 (sl) 2021-12-31
KR20140036324A (ko) 2014-03-25
US20190276456A1 (en) 2019-09-12
AU2017279778B2 (en) 2019-09-19
SMT201900029T1 (it) 2019-02-28
US20180179212A1 (en) 2018-06-28
CL2014000130A1 (es) 2014-08-22
IL266894B (en) 2022-04-01
JP2018035184A (ja) 2018-03-08
SI2734522T1 (sl) 2019-03-29
PL2734522T3 (pl) 2019-04-30
IN2014CN00408A (h) 2015-04-03
EA037644B1 (ru) 2021-04-26
EP2734522A1 (en) 2014-05-28
PH12017500166B1 (en) 2018-10-26
US9790226B2 (en) 2017-10-17
WO2013010868A1 (en) 2013-01-24
NZ716110A (en) 2017-07-28
US9290504B2 (en) 2016-03-22
DK3689878T3 (da) 2021-11-08
EA201992270A2 (ru) 2020-01-16
EA201992270A3 (ru) 2020-03-31
ZA202109164B (en) 2025-04-30
CY2021010I2 (el) 2021-06-25
CY1125613T1 (el) 2024-02-16
JP2022088618A (ja) 2022-06-14
IL230511A0 (en) 2014-03-31
EP4249076A3 (en) 2023-11-01
EP2734522B1 (en) 2018-10-31
EA034558B1 (ru) 2020-02-20
CN103889987B (zh) 2016-09-14
UA115312C2 (uk) 2017-10-25
MA35348B1 (fr) 2014-08-01
AU2016203837A1 (en) 2016-06-30
AU2017279778A1 (en) 2018-01-25
CN103889987A (zh) 2014-06-25
PL3689878T3 (pl) 2022-02-14
EP3689878B1 (en) 2021-10-06
US10934296B2 (en) 2021-03-02

Similar Documents

Publication Publication Date Title
CY2021010I1 (el) 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4-ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ
EP2734529A4 (en) BTK INHIBITORS
CO6920291A2 (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante
LT2841428T (lt) Dnr-pk inhibitoriai
BR112014002399A2 (pt) conjunto
BR112013024052A2 (pt) artigo absorvente
CO6880068A2 (es) Aminoquinazolinas como inhibidores de quinasa
CO6990717A2 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
CU24164B1 (es) Inhibidores sustituidos de acetil-coa carboxilasa
DE102011100082A8 (de) Traygreifvorrichtung
BR112014000879A2 (pt) deflegmador
EP2682082A4 (en) Tampon applicator
CO6960543A2 (es) 2-tiopirimidinonas
BR112014000003A2 (pt) artigo absorvente
EP2794841A4 (en) BIOREACTOR
FI20116167L (fi) Järjestely
EP2810665A4 (en) bio-implant
DE112011104936A5 (de) Stanzstauchniet
EP2697183A4 (en) composter
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012003417A5 (de) Strommessgerät
DE112012002458A5 (de) Hydrotransformator
DE112012000819A5 (de) Gurtbandfänger
DE112012005313A5 (de) Leuchtbild